Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 9/20 | 0.53 |
| ▸ | SRD5A2 | P31213 | 9/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | HSD3B1 | P14060 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | THPO | P40225 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL950330 | 1.00 | SRD5A1 (0.53) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL950331 | 1.00 | SRD5A1 (0.53) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Imidazole SCHEMBL9187249 | 0.88 | SRD5A2 (0.45) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL6673554 | 0.85 | SRD5A1 (0.42) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL8059923 | 0.81 | SRD5A1 (0.48) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL8135268 | 0.81 | SRD5A1 (0.53) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL8135264 | 0.81 | SRD5A1 (0.53) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL4263946 | 0.80 | SRD5A1 (0.53) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL4263941 | 0.80 | SRD5A1 (0.53) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL7901226 | 0.79 | SRD5A1 (0.55) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0862556-A4 | 17-ALKYL-7-SUBSTITUTED-4-AZA STEROID DERIVATIVES | MERCK & CO INC (US) | 1999-02-03 | — | — | EP | claimed |
| EP-0862556-A1 | 17-ALKYL-7-SUBSTITUTED-4-AZA STEROID DERIVATIVES | Merck & Co., Inc. (US) | 1998-09-09 | — | — | EP | claimed |
| WO-1998009632-A1 | METHODS AND COMPOSITIONS FOR TREATING PRETERM LABOR | MERCK & CO., INC. (US) | 1998-03-12 | — | — | WO | claimed |
| WO-1997015558-A1 | 17-ALKYL-7-SUBSTITUTED-4-AZA STEROID DERIVATIVES | MERCK & CO., INC. (US) | 1997-05-01 | — | — | WO | claimed |
| EP-0649431-A4 | 17-AMINO SUBSTITUTED 4-AZASTEROID 5-G(A)-REDUCTASE INHIBITORS. | — | 1995-05-03 | — | — | EP | claimed |
| EP-0649431-A1 | 17-AMINO SUBSTITUTED 4-AZASTEROID 5$g(a)-REDUCTASE INHIBITORS | MERCK & CO. INC. (US) | 1995-04-26 | — | — | EP | claimed |
| US-8591874-B2 | Inhibition of mammalian hair growth | THE PROCTER & GAMBLE COMPANY (US) | 2013-11-26 | — | — | US | disclosed |
| US-8481015-B2 | Applying agmatine and a dermatologically acceptable carrier to the skin; inhibiting hair growth | THE PROCTER & GAMBLE COMPANY (US) | 2013-07-09 | — | — | US | disclosed |
| WO-2012035553-A1 | PROCESS FOR PREPARING ANDROSTENONE DERIVATIVES | IND-SWIFT LABORATORIES LIMITED (IN) | 2012-03-22 | — | — | WO | disclosed |
| EP-1622567-A4 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | MERCK & CO INC (US) | 2009-04-29 | — | — | EP | disclosed |
| US-7432302-B2 | Composition containing polyamine transport inhibitor and use thereof | MEDIQUEST THERAPEUTICS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-20080188505-A1 | Regulation of Mammalian Hair Growth | OBLONG JOHN ERICH | 2008-08-07 | — | — | US | disclosed |
| US-20080119503-A1 | Androgen receptor modulators and methods of use thereof | MERCK SHARP & DOHME CORP. | 2008-05-22 | — | — | US | disclosed |
| US-4859681-A | 17 α-Acyl-4-aza-5a-androst-1-en-3-ones as 5 alpha-reductase inhibitors | MERCK & CO., INC. (US) | 1989-08-22 | — | — | US | disclosed |
| EP-0314199-A1 | 17 Beta-substituted-4-aza-5 alpha-androstenones and their use as 5 alpha-reductase inhibitors | MERCK & CO. INC. (US) | 1989-05-03 | — | — | EP | disclosed |
| EP-0314199-A1 | 17 Beta-substituted-4-aza-5 alpha-androstenones and their use as 5 alpha-reductase inhibitors | MERCK & CO. INC. (US) | 1989-05-03 | — | — | EP | disclosed |
| EP-0285383-A2 | Treatment of prostatic carcinoma with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones | MERCK & CO. INC. (US) | 1988-10-05 | — | — | EP | disclosed |
| EP-0285382-A2 | Treatment of androgenic alopecia with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones | MERCK & CO. INC. (US) | 1988-10-05 | — | — | EP | disclosed |
| US-4760071-A | Enzyme inhibitor | MERCK & CO., INC. (US) | 1988-07-26 | — | — | US | disclosed |
| EP-0271219-A1 | Topical pharmaceutical composition containing 17-beta-methoxycarbonyl-4-methyl-4-aza-5-alpha-androst-1-en-3-one | MERCK & CO. INC. (US) | 1988-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188505-A1 | Regulation of Mammalian Hair Growth | BHMT, UGCG, HNMT | SRD5A1 1584/4885SRD5A2 2384/4885LMNA 1608/4885 |
| US-20080119503-A1 | Androgen receptor modulators and methods of use thereof | SHBG, FSHR, AR | SRD5A1 42/4885SRD5A2 57/4885LMNA 2056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.